MedTrace Logo

TONKA Versus Legalon for Lowering Hepatic Enzymes in Liver Function Disorder Patients.

NCT03216668 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 140

Last updated 2018-10-23

No results posted yet for this study

Summary

The purpose of this study is to evaluate the efficacy TONKA on the reduction of ALT and AST in moderate to severe liver enzyme elevated patients; compared with Silymarin (Legalon) after 6 weeks of treatment.

Conditions

  • Liver Function Failure

Interventions

DRUG

TONKA

Administered orally twice a day, 2 tablets each time, for 6 weeks.

DRUG

LEGALON

Administered orally three times a day, two tablets each time, for 6 weeks

Sponsors & Collaborators

  • Nhat Nhat Pharmaceutical Company

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-06-15
Primary Completion
2019-06-30
Completion
2019-09-30

Countries

  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03216668 on ClinicalTrials.gov